immutep limited (asx:imm, nasdaq:immp) encouraging results for immutep's cancer therapies
Published 6 months ago • 322 plays • Length 10:01
Download video MP4
Download video MP3
Similar videos
-
4:40
immutep (asx:imm, nasdaq:immp) announces encouraging trial data for lung cancer therapy
-
4:44
immutep (asx:imm, nasdaq:immp) - innovative cancer therapies
-
8:42
immutep (asx:imm) announces positive results in head and neck cancer treatment
-
6:25
immutep (asx:imm, nasdaq:immp) discusses a transformative year for lag-3 therapies
-
56:38
immutep (asx:imm, nasdaq:immp) webcast for tacti-002 data presented at asco 2022 - 10 jun 2022
-
7:09
immutep (asx:imm, nasdaq:immp) reports 71.4% response rate for lung cancer therapy, october 31, 2023
-
47:53
immutep (asx:imm, nasdaq:immp) tacti-003 results, june 2024
-
3:33
immutep (asx:imm) reports positive trial data
-
52:08
immutep (asx:imm, nasdaq:immp) global webcast presentation at sitc 2022
-
15:49
immutep (asx:imm) - webinar presentation
-
16:06
immutep (asx:imm) - webinar presentation
-
4:32
immutep limited (asx:imm; nasdaq:immp) ceo and executive director marc voigt provides company update
-
12:28
immutep (asx:imm, nasdaq:immp) ceo marc voigt provides an update on clinical trials
-
1:14:06
immutep (asx:imm) sitc 2021 results - management update
-
50:22
immutep (asx:imm, nasdaq:immp) esmo congress results webinar, 23 october 2023
-
7:43
immutep (asx:imm; nasdaq: immp) company update on start of 2021
-
5:42
immutep (asx:imm, nasdaq:immp) receives fast track designation from fda - october 12, 2022
-
27:17
immutep limited (asx:imm, nasdaq:immp) - fireside chat with immutep limited
Clip.africa.com - Privacy-policy